Inflectra Injection, Powder, Lyophilized, For Solution
Product Images NDC 0069-0809

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Inflectra (NDC 0069-0809). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Inflectra 01)

A line graph showing the percentage of patients who had not lost response over 54 weeks. The X-axis represents study weeks from 0 to 54, and the Y-axis represents the percentage of patients from 0% to 100%. Three treatment groups are compared: placebo maintenance, 5 mg/kg infliximab maintenance, and 10 mg/kg infliximab maintenance. The graph shows a higher percentage of patients maintaining response with infliximab versus placebo over time.*

FDA Label Image

Figure 2 (Inflectra 02)

A line graph showing the percentage of patients who had not lost response over a 54-week study period. Two groups are compared: placebo maintenance (open circles) and 5 mg/kg infliximab maintenance (filled circles). The infliximab group maintains a higher percentage of response throughout the study, with statistical significance noted (p = 0.001) compared to placebo.*

FDA Label Image

Figure 3 (Inflectra 03)

A line graph comparing the proportion of patients (%) over 24 weeks between placebo and infliximab 5 mg/kg treatments. The Y-axis shows patient proportion from 0% to 100%, and the X-axis shows time in weeks (0 to 24). Infliximab treatment shows a significantly higher proportion of patients responding than placebo at multiple time points, denoted by asterisks indicating statistical significance (P < 0.001).*

FDA Label Image

Figure 4 (Inflectra 04)

A line chart illustrating the percent of patients over a 50-week period, comparing four groups receiving infliximab-dyyb at different doses (3 mg/kg and 5 mg/kg) and schedules (every 8 weeks or PRN). The x-axis represents weeks, and the y-axis shows the percent of patients, with data points connected for each treatment group.*

FDA Label Image

Logo (Inflectra 05)

FDA Label Image

Principal Display Panel (100 mg Vial Label)

FDA Label Image

Principal Display Panel (100 mg Vial Carton)

Label for Inflectra (infliximab-dyyb) injection, powder, lyophilized, for solution, 100 mg per vial. Intended for intravenous infusion only, single-dose vial. Storage instructions and manufacturer information from Pfizer Labs and Celltrion, Inc. are included on the label.*

FDA Label Image

Inflectra 08

Packaging label for INFLECTRA (infliximab-dyyb) injection, powder, lyophilized, for solution with a strength of 100 mg per vial. The label indicates it is for intravenous infusion only, single-dose vial, and includes storage instructions, dosage preparation, and manufacturer details. The labeler is Pfizer Laboratories Div Pfizer Inc, with NDC 0069-0809-01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.